Text Size: A A A      Contrast:        Transparency in Coverage Rule

New Eye Drops Study to begin for Treatment of AMD

Retina Associates will Participate in an Exciting New Clinical Trial Using Eye Drops for the Treatment of Wet Age-related Macular Degeneration (wet AMD)Retina Associates of Cleveland, Inc. (RACI) has secured 1 of only 21 clinical trial locations across the U.S. set to begin Phase II evaluation of a promising new treatment for wet AMD, Squalamine Eye Drops made by Ohr Pharmaceutical.  RACI will be the only clinical site in the state of Ohio offering the new drops to qualified patients enrolled in the randomized, double blind, placebo controlled study evaluating the safety and efficacy of the new treatment and its success in combating the progression of wet AMD. 

Current treatments for wet AMD involve injections directly into the eye of drugs including Lucentis, Avastin and Eylea, designed to slow the growth of abnormal, leaky blood vessels caused by vascular endothelial growth factor (VEGF) proteins which can lead to severe vision loss.  These treatments must be repeated every month or two and as such can be quite costly.  According to the National Eye Institute (NEI), 1.75 million adults 40 years or older in the U.S. suffer from wet AMD, which is the leading cause of blindness in the elderly population.

Lawrence J. Singerman, MD of Retina Associates is a member of Ohr Pharmaceutical’s Advisory Board.  He recently commented in a press release, “I am very excited to be participating in the clinical study of this potentially groundbreaking product.  The addition of a self-administered eye drop to treat wet AMD as an alternative or adjunctive therapy to our current treatment modalities would be a tremendous step forward for patients who suffer from this debilitating condition.”

Retina Associates of Cleveland has 8 office locations across NE Ohio and nine retinal specialists, all of whom are very active in clinical research and will be participating in this new study.  Office locations include Akron, Beachwood, Lakewood, Lorain, Mentor, Middleburg Heights, Warren and Youngstown.  Interim results for the squalamine study are expected the 4th quarter of 2013.  For more information on this study, please call Retina Associates’ Beachwood office at (216)831-5700.